Related party transactions
On 30 April 2021, the members of the management board were offered new subscription rights under Subscription Right Plan 2021 BE, subject to acceptance. The final number of accepted subscription rights under Subscription Right Plan 2021 BE, Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW were enacted by notary deed on 2 July 2021 and on 18 August 2021. The subscription rights have an exercise term of eight years as of the date of the offer. The exercise price of the subscription rights is €64.76 (the closing price of the Galapagos share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). Each subscription right gives the right to subscribe for one new Galapagos share. For all the beneficiaries under Subscription Right Plan 2021 BE the subscription rights vest only and fully on the first day of the fourth calendar year following the calendar year in which the grant was made. The subscription rights are not transferable and can in principle not be exercised prior to 1 January 2025. Subscription rights granted under Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW vest in instalments: with 25% of each grant being exercisable as of 1 January 2023, 25% as of 1 January 2024 and 50% (the remainder) as of 1 January 2025.
On 5 May 2021 and on 24 September 2021, the members of the management board were offered new restricted stock units (‘RSUs’), subject to acceptance. The RSUs are offered for no consideration. Under the first RSU grant, four members of the management board accepted all RSUs offered to them. Under the second RSU grant, five members of the management board accepted all RSUs offered to them. Each RSU represents the right to receive, at Galapagos’ discretion, one Galapagos share or a payment in cash of an amount equivalent to the volume-weighted average price of the Galapagos share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The first RSU grant will vest in full three years after the offer date. The second RSU grant has a four-year vesting period, with 25% vesting each year and a first vesting date on 1 May 2022. For the members of the management board, any vesting prior to the third anniversary of the offer date will always give rise to a payment in cash rather than a delivery of shares. The RSUs are not transferable.
The table below sets forth the number of subscription rights accepted under Subscription Right Plan 2021 BE and the total number of RSUs accepted by each member of the management board during the first nine months of 2021:
Name |
Title |
Number of 2021 subscription rights accepted |
Number of 2021 RSUs accepted |
---|---|---|---|
Onno van de Stolpe |
Chief Executive Officer |
85,000 |
63,830 |
Bart Filius |
President & Chief Operating Officer |
50,000 |
62,730 |
Walid Abi-Saab |
Chief Medical Officer |
40,000 |
44,038 |
Piet Wigerinck |
Chief Scientific Officer |
40,000 |
- |
Andre Hoekema |
Chief Business Officer |
30,000 |
51,433 |
Michele Manto |
Chief Commercial Officer |
30,000 |
31,694 |
During the first nine months of 2021, there were no changes to related party transactions disclosed in the 2020 annual report that potentially had a material impact on the financials of the first nine months of 2021.